Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma

Liver International

Volumn 33, Issue 6, 2013, Pages 944-949

  Tsochatzis, Emmanuel ^a   Garcovich, Matteo ^a   Marelli, Laura ^a   Papastergiou, Vassilis ^a   Fatourou, Evangelia ^a   Rodriguez Peralvarez, Manuel L ^a   Germani, Giacomo ^a   Davies, Neil ^b   Yu, Dominic ^b   Luong, Tu Vinh ^a   Dhillon, Amar P ^a   Thorburn, Douglas ^a   Patch, David ^a   O'Beirne, James ^a   Meyer, Tim ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

HCC; Liver transplant; Recurrence; Survival; TACE; TAE

Indexed keywords

POLYVINYL ALCOHOL;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; FEMALE; HEALTH CARE QUALITY; HUMAN; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY;

CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECROSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; POLYVINYL ALCOHOL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84878930509     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12144     Document Type: Article

References (27)

1. ELTR database. Available at. http://www.eltr org/spip php?article161 2012. Accessed 01 June 2012.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
3. Maggs JR, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 1113-34.
4. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684-92.
5. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644-50.
6. Tsochatzis EA, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 2010; 37: 89-93.
7. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
8. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolization for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; CD004787.
9. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
10. Cucchetti A, Cescon M, Bigonzi E, et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344-54.
11. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-75.
12. Millonig G, Graziadei IW, Freund MC, et al. Response to pre-operative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-9.
13. Jang JW, You CR, Kim CW, et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415-23.
14. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 2007; 30: 6-25.
15. Barber K, Madden S, Allen J, et al. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 2011; 92: 469-76.
16. Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007; 33: 437-47.
17. Meyer T, Roughton M, Yu D, et al. A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC). J Clin Oncol 2010; 28(Suppl. 1): 15s.
18. Majno PE, Adam R, Bismuth H, et al. Influence of pre-operative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701.
19. Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12: 665-73.
20. Oldhafer KJ, Chavan A, Fruhauf NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumour necrosis, but no survival benefit? J Hepatol 1998; 29: 953-9.
21. Tsochatzis EA, Meyer T, Burroughs AK. Hepatocellular carcinoma. N Engl J Med 2012; 366: 92-3.
22. Perez SB, Meneu JC, Moreno E, et al. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg 2005; 190: 383-7.
23. Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123-8.
24. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
25. Tsochatzis E, Meyer T, Marelli L, Burroughs AK. Which transarterial therapy is best for hepatocellular carcinoma?-the evidence to date. J Hepatol 2010; 53: 588.
26. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 541-51.
27. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.